BioSpace News Archive

Verismo Therapeutics, a clinical-stage CAR-T company and University of Pennsylvania spinout developing novel KIR-CAR platform technology, today announced that it has activated its STAR-101 Phase 1 clinical trial at the University of Pennsylvania.

Conventus Flower Orthopedics, an innovation-driven medical technology company, announced the appointment of Anjan R. Shah, MD as its Chief Medical Officer.

BostonGene Corporation has announced a major research collaboration with Australia’s Mater Research to discover novel diagnostic biomarkers of follicular lymphoma and ultimately improve treatment for patients in the advanced stages of the disease.

The Insight Partners published latest research report on “Biopharmaceutical Tubing Market Size Report, Share, Trends, Growth & Forecast to 2028 - COVID-19 Impact and Global Analysis By Type and Application”,

BioCentriq, Inc. and panCELLa, a Pluristyx Company, announced that they have signed a research agreement designed to evaluate the ability of panCELLa’s genetically-engineered, induced Pluripotent Stem Cell (iPSC)-derived, feeder cells to activate and positively impact the expansion rate, total yield and potency of manufactured NK cells.

Today, the U.S. Food and Drug Administration is taking additional steps to support the use of decentralized clinical trials (DCTs) for drugs, biologics and devices, where some or all the trial-related activities occur at locations other than traditional clinical trial sites.

Bioxodes SA, a company specializing in the development of novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, today announces it has been selected to present at key international business and scientific conferences this spring and early summer:

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased to announce it has engaged Chris McNorgan, PhD, to drive a license agreement of NCP-01 with a company who is pursuing neural electrode-based brain intervention.

Abivax SA announces the Journal of Crohn’s and Colitis publication of a piece titled " Obefazimod: a first-in-class drug for the treatment of ulcerative colitis " [1], written by global Inflammatory Bowel Disease experts.

Boston Immune Technologies and Therapeutics, Inc., a privately held developer of novel tumor necrosis factor superfamily receptor antagonist antibodies, announced that the company will be presenting new data from its CD40 program at Immunology2023, the annual meeting of the American Association of Immunologists.